Australia's most trusted
source of pharma news
Monday, 06 May 2024
Posted 22 April 2024 AM
Pfizer's Cibinqo has finally arrived in Australia, joining the company's other JAK inhibitor Xeljanz.
Cibinqo, which belongs to the same drug class as AbbVie's Rinvoq, Eli Lilly's Olumiant, and Novartis' Jakavi has been TGA approved for the treatment of moderate to severe atopic dermatitis in adults who are candidates for systemic therapy.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.